00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking more...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Tenofovir alafenamide fumarate: Phase III data

Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif.   Product: Tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine (formerly GS-7340/elvitegravir/cobicistat/emtricitabine)   Business: Infectious   Molecular target: NA   Description: Co-formulated single-tablet regimen of tenofovir alafenamide fumarate (TAF), a prodrug of tenofovir, a...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial launches...
08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Shooting F-stars

F-star Alpha Ltd.'s deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller financial...
07:00 , Jul 28, 2014 |  BioCentury  |  Finance

Staying the course with half a billion

Sofinnova Ventures is sticking with what works for its second life sciences-only fund, which the firm closed last week at $500 million. The fund, the firm's ninth overall, was oversubscribed and was originally targeting $425 million....
07:00 , Apr 28, 2014 |  BioCentury  |  Finance

Venture hots up

Private biotechs have raised $3.1 billion since the start of the year, double the $1.5 billion raised in the same period last year. At least one investor contacted by BioCentury expects the pace to continue...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Gilead sales and marketing update

Gilead recalled two lots of HIV drug Atripla emtricitabine/tenofovir/ efavirenz due to the presence of red silicone rubber particulates. Gilead said the lots, which include about 40,000 bottles total, were distributed to pharmacies in...
08:00 , Feb 10, 2014 |  BioCentury  |  Finance

Confident roll of the dice(r)

Underwriters for Dicerna Pharmaceuticals Inc.'s IPO took the rare step of waiving a lockup period for the RNAi play - a move that could give some existing shareholders a free hand to immediately realize some...